Headline Medical News: June 2018

CT-132 is a 12-week app-based intervention that uses validated behavioral techniques to modulate labile brain circuitry involved in migraine, according to Click Therapeutics.

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Your daily dose of the clinical news you may have missed.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Data from the EAGLE-1 study found gepotidacin to be noninferior to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhea.

Gestational diabetes and hypertensive disorders of pregnancy may be markers for rather than mediators of risk for future CVD, according to new research.